UBS Maintains a 'Buy' on DaVita (DVA); Solid Results; Now Focus Shifts to Integrated Care
Tweet
Share
E-mailGet Alerts DVA Hot Sheet
Price: $133.91 +1.05%
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
UBS maintains a 'Buy' on DaVita (NYSE: DVA) price target raised from $98 to $100.
UBS analyst says, "Q411 EPS of $1.58 was well ahead of UBS/Consensus of $1.46/$1.49 with operating income of $330m (vs. $319m UBS) on lower patient care costs w/ cost per treatment of $208.66, down 3.2% seq. and nearly $7 below our est while better taxes added $0.04 to beat."
"Integrated care opportunity well-vetted on call both by CEO Kent Thiry and sell-side w/ 75% of analysts asking at least one question on topic. Co remains confident that LT remains intact, with a potential RFP from CMS coming as early as the first half of 2012 for 2013 start. We see this as potentially one of the largest green-field opportunities in provider segment and key to our positive view on the stock, with our DCF pointing to more than $30 per share upside."
UBS raises FY12/13 EPS estimate by $0.05 each, to $6.35 and $7.40, respectively.
For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.
Shares of DaVita closed at $85.48 yesterday.
UBS analyst says, "Q411 EPS of $1.58 was well ahead of UBS/Consensus of $1.46/$1.49 with operating income of $330m (vs. $319m UBS) on lower patient care costs w/ cost per treatment of $208.66, down 3.2% seq. and nearly $7 below our est while better taxes added $0.04 to beat."
"Integrated care opportunity well-vetted on call both by CEO Kent Thiry and sell-side w/ 75% of analysts asking at least one question on topic. Co remains confident that LT remains intact, with a potential RFP from CMS coming as early as the first half of 2012 for 2013 start. We see this as potentially one of the largest green-field opportunities in provider segment and key to our positive view on the stock, with our DCF pointing to more than $30 per share upside."
UBS raises FY12/13 EPS estimate by $0.05 each, to $6.35 and $7.40, respectively.
For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.
Shares of DaVita closed at $85.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FI) PT Raised to $175 at TD Cowen
- Boston Beer Company (SAM) PT Lowered to $325 at Jefferies
- Nomura/Instinet Downgrades Gujarat State Petronet (GUJS:IN) to Reduce
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
